In WT KRAS mCRC , PFS was improved , objective response was higher , and there was a trend toward improved OS with panitumumab-FOLFOX4 , with significant improvement in OS observed in an updated analysis of survival in patients with WT KRAS mCRC treated with panitumumab + FOLFOX4 versus FOLFOX4 alone ( P = 0.03 ) .